Abraxis BioScience, Inc. (ABII)
Recs
This is a real company with a real product. If the numbers below are accurate, they are a good buy.
VS industry:
Price to Book (MRQ) 1.19 3.72
Price to Tangible Book (MRQ) 2.20 8.52
LT Debt to Equity (MRQ) 0.00 0.38
Total Debt to Equity (MRQ) 0.00 0.42
Recs
New 52 week low. Has declined by 2/3 from 52 week high. New management in place. Oncology products company with promising pipeline.
Recs
If a history is any indication, then consider the PFE. A few year ago, it was trading at 150 times 12 month trail earning or about $150.00 per share. Within two-three week after achieving 150 times, it dived to $100 per share. Rest is his a history.
Newness doesn't justify 179 times. It seens a but scart to me. This is my way of kicking some tires.
Recs
i may trust here
Recs
One drug on the market with a nice platform to build similar drugs. The spin off (and ticker change) has made this an unknown company which could cause its stock price to falter a little. Still there's points to be made in unknown companies.
Holding the actual dollars away from this one until it gets regular with its earnings announcements. We're less than a week away from the end of the 1st quarter and there's no sign of 4th quarter financial info. The spin off is holding things up, but I figure it makes since to invest in companies based on current information.

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 5 of 5